中文摘要：本发明涉及七鳃鳗或八目鳗类鱼可变白细胞受体（VLR）C端区域的作用。该区域可以作为炎症、自免疫疾病或癌症等不同疫苗的载体蛋白进行应用。
外文摘要：The invention relates to the use of the C terminal region of Lamprey or Hagfish variable leukocyte receptor (VLR) as fusion partner in various vaccine antigens to be used in therapeutic or preventive vaccine formulations for the treatment of inflammatory, autoimmune conditions or cancer.
NOVELTY - A vaccine comprising target antigen, or part or its fragment, being fused to a fusion partner, and optionally adjuvant, is new. The fusion partner is entire or any part of C terminal pentamerizing (multimerizing) region of the hagfish or lamprey variable leukocyte receptor (VLR-A, B or C), in its original or slightly mutated, functionally equivalent form.
USE - The vaccine is useful for stimulating the immune system to induce a strong therapeutic or preventive antibody response against any therapeutic target self or non-self-antigen or protein composition, or preventing or treating cancer, tumors, allergic inflammation, autoimmune disorders or other inflammatory conditions. The method is useful for inhibiting tumor growth, metastasis or inducing stable disease, or preventing or treating inflammatory conditions or autoimmune disorders in a patient (all claimed).
 
主权项：(1) fusion partner to generate a vaccine antigen to target various self or non-self-proteins in a preventive or therapeutic vaccine composition; and
(2) method for inhibiting tumor growth, metastasis or inducing stable disease, or preventing or treating inflammatory conditions or autoimmune disorders in a patient, involves administering the vaccine composition to patient.
 
申请号：WO2016SE00056
公开/公告号：WO2017074235A1
申请日：2016-10-12
公开/公告日：2017-05-04
申请/专利权人：THERAVAC PHARM AB (THER-N)
发明/设计人：OLSSON, A;HELLMAN, L;SAUPE, F
分类号：C07K14/46; C07K19/00; C12N15/62
主分类号：A61P37/00; C07K14/46; C07K19/00; C12N15/62
点击下载：一种用于生产安全疫苗的新型载体蛋白